






# Methylation profiling report

## General information

Sentrix ID: 203939360072\_R04C01  
Array type: EPIC  
Material type: FFPE DNA  
Gender: female

## Brain tumor methylation classifier results (v11b4)

Methylation classes (MCs with score $\geq 0.3$ )	Calibrated score	Interpretation
methylation class family Medulloblastoma group 3 and 4	0.95	match 
<b>MC family members with score <math>\geq 0.1</math></b>		
methylation class medulloblastoma, subclass group 3	0.93	match 


Legend:  Match (score  $\geq 0.9$ )  No match (score  $< 0.9$ ): possibly still relevant for low tumor content and low DNA quality cases.  Match to MC family member (score  $\geq 0.5$ )

## Class descriptions

**Methylation class family Medulloblastoma group 3 and 4:** The methylation class family "Medulloblastoma class 3 and 4" comprises the methylation classes medulloblastoma, class 3 and medulloblastoma, class 4.

**Methylation class medulloblastoma, subclass group 3:** The methylation class "medulloblastoma, subclass group 3" is comprised of tumors with the diagnosis medulloblastoma, genetically defined, group 3. Histologically most cases fall into the classical and large cell/anaplastic groups. Tumors are located in the cerebellum, typically in the vermis. Median age is 4 years (range 1 to 17). Group 3 medulloblastomas are more common in males than females. MYC amplification, aneuploidy, isochromosome 17q and GF11/1B activation by enhancer hijacking are recurrent features, but a fraction lack an obvious driving genetic change.


## Copy number variation profile



Depiction of chromosome 1 to 22 (and X/Y if automatic prediction was successful). Gains/amplifications represent positive, losses negative deviations from the baseline. 29 brain tumor relevant gene regions are highlighted for easier assessment.

(see Hovestadt & Zapatka, <http://www.bioconductor.org/packages/devel/bioc/html/conumee.html>)

# MGMT promotor methylation (MGMT-STP27)



(see Bady et al, J Mol Diagn 2016; 18(3):350-61)

## Disclaimer

Classification using methylation profiling is a research tool under development, it is not verified and has not been clinically validated. Implementation of the results in a clinical setting is in the sole responsibility of the treating physician. Intended for non-commercial use only.

## Run information

Report: idat\_reportBrain\_v11b4 Version 2.0  
Task version:

Task	Version
idat_qc	2.0
idat_predictBrain	2.1
idat_rs_gender	2.0
idat_predictMGMT	2.0
idat_cnvp	3.0